Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
219 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dementia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape. Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 17, 33, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively. Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 9 Global Markets Direct Report Coverage 9 Dementia - Overview 10 Dementia - Therapeutics Development 11 Pipeline Overview 11 Pipeline by Companies 12 Pipeline by Universities/Institutes 17 Products under Development by Companies 19 Products under Development by Universities/Institutes 24 Dementia - Therapeutics Assessment 25 Assessment by Target 25 Assessment by Mechanism of Action 29 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Dementia - Companies Involved in Therapeutics Development 36 Acorda Therapeutics Inc 36 Actinogen Medical Ltd 36 Adamas Pharmaceuticals Inc 37 AgeneBio Inc 37 Alector LLC 38 Allergan Plc 38 AlzProtect SAS 39 Amarantus Bioscience Holdings Inc 39 Anavex Life Sciences Corp 40 Asceneuron SA 40 Axon Neuroscience SE 41 Axovant Sciences Ltd. 41 BioArtic AB 42 Biogen Inc 42 Boehringer Ingelheim GmbH 43 Cortice Biosciences Inc 43 Daewoong Pharmaceutical Co Ltd 44 Echo Pharmaceuticals BV 44 Eisai Co Ltd 45 Eli Lilly and Company 45 H. Lundbeck A/S 46 Heptares Therapeutics Ltd 47 HSRx Group 47 Hyundai Pharmaceutical Co Ltd 48 Ildong Pharmaceutical Co Ltd 48 Immungenetics AG 49 ImStar Therapeutics Inc 49 Integrative Research Laboratories Sweden AB 50 Intellect Neurosciences Inc 50 INVENT Pharmaceuticals Inc 51 Ironwood Pharmaceuticals Inc 51 M3 Biotechnology Inc 52 MediPost Co Ltd 52 Neuraltus Pharmaceuticals Inc 53 Neurimmune Holding AG 53 Neuropore Therapies Inc 54 NsGene A/S 54 Oryzon Genomics SA 55 P2D Bioscience 55 Pacific Northwest Biotechnology LLC 56 Pharmasum Therapeutics AS 56 Prana Biotechnology Ltd 57 Sage Therapeutics Inc 57 Sinil Pharmaceutical Co Ltd 58 Stelic Institute & Co Inc 58 Stemedica Cell Technologies Inc 59 Sumitomo Dainippon Pharma Co Ltd 59 Suven Life Sciences Ltd 60 Sylentis SAU 60 TauRx Therapeutics Ltd 61 Voyager Therapeutics Inc 61 WhanIn Pharmaceutical Co Ltd 62 Zhejiang Hisun Pharmaceutical Co Ltd 62 Dementia - Drug Profiles 63 (donepezil hydrochloride + glycopyrrolate) - Drug Profile 63 (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 64 (donepezil hydrochloride + solifenacin succinate) - Drug Profile 66 (glycopyrrolate + rivastigmine) - Drug Profile 68 AADvac-1 - Drug Profile 69 AD-35 - Drug Profile 71 ANAVEX-371 - Drug Profile 72 Antibody to Inhibit Tau Proteins for Corticobasal Degeneration - Drug Profile 74 Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 75 ASN-561 - Drug Profile 76 AZP-2006 - Drug Profile 77 BAN-0805 - Drug Profile 79 BI-409306 - Drug Profile 80 CB-2233 - Drug Profile 82 CB-8411 - Drug Profile 83 Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile 84 choline alfoscerate SR - Drug Profile 85 CIDEM-162 - Drug Profile 86 D-217 - Drug Profile 87 dehydroevodiamine hydrochloride - Drug Profile 88 donepezil Depot - Drug Profile 89 donepezil Patch - Drug Profile 90 dronabinol - Drug Profile 91 Drugs for Dementia - Drug Profile 93 Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile 94 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95 DWJ-1365 - Drug Profile 96 E-2027 - Drug Profile 97 E-2609 - Drug Profile 98 eltoprazine - Drug Profile 101 GIBH-130 - Drug Profile 106 Gln-1062 - Drug Profile 107 GTC-6000 - Drug Profile 110 gugulipid - Drug Profile 111 HOB-075 - Drug Profile 112 HTL-18318 - Drug Profile 113 intepirdine - Drug Profile 114 INV-331 - Drug Profile 117 IRL-752 - Drug Profile 118 IW-6463 - Drug Profile 119 landipirdine - Drug Profile 120 levetiracetam - Drug Profile 122 LUAF-20513 - Drug Profile 124 MM-201 - Drug Profile 125 Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile 126 Monoclonal Antibodies to Inhibit SORT1 for Alzheimer's Disease and Dementia - Drug Profile 127 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 128 Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 129 monosodium luminol - Drug Profile 130 NAT - Drug Profile 132 nelotanserin - Drug Profile 133 Neurostem - Drug Profile 135 NI-205 - Drug Profile 137 NI-308 - Drug Profile 138 NNC-269100 - Drug Profile 139 NP-001 - Drug Profile 140 NPT100-18A - Drug Profile 143 NXN-413 - Drug Profile 144 NXN-613 - Drug Profile 145 ORY-2001 - Drug Profile 146 PAM-43 - Drug Profile 149 PBT-434 - Drug Profile 150 PD-2015 - Drug Profile 152 PD-2024 - Drug Profile 153 PD-2244 - Drug Profile 154 Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 155 PST-900 - Drug Profile 156 rivastigmine - Drug Profile 157 salicylamine - Drug Profile 158 SGE-201 - Drug Profile 159 SIN-1502 - Drug Profile 160 Small Molecule for Vascular Dementia - Drug Profile 161 Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 162 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 163 Small Molecule to Agonize Dopamine D1 Receptor for Dementia Associated with Alzheimer's Disease - Drug Profile 164 Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 165 Small Molecule to Inhibit TNF-Alpha for CNS Disorders - Drug Profile 166 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 167 Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 168 Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Central Nervous System - Drug Profile 169 Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 170 SND-14 - Drug Profile 171 Stem Cell Therapy for Dementia Associated with Alzheimer's Disease - Drug Profile 172 SUVNI-1307014 - Drug Profile 174 SUVNI-1312004 - Drug Profile 175 Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 176 TAK-070 - Drug Profile 177 TauC-3 - Drug Profile 178 tolfenamic acid - Drug Profile 180 TPI-287 - Drug Profile 181 TRx-0237 - Drug Profile 185 UE-2343 - Drug Profile 189 VYTAU-01 - Drug Profile 192 WIB-1001C - Drug Profile 193 zonisamide - Drug Profile 194 Dementia - Dormant Projects 196 Dementia - Discontinued Products 200 Dementia - Product Development Milestones 201 Featured News & Press Releases 201 Appendix 212 Methodology 212 Coverage 212 Secondary Research 212 Primary Research 212 Expert Panel Validation 212 Contact Us 212 Disclaimer 213
List of Tables
Number of Products under Development for Dementia, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Dementia - Pipeline by Acorda Therapeutics Inc, H1 2017 Dementia - Pipeline by Actinogen Medical Ltd, H1 2017 Dementia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017 Dementia - Pipeline by AgeneBio Inc, H1 2017 Dementia - Pipeline by Alector LLC, H1 2017 Dementia - Pipeline by Allergan Plc, H1 2017 Dementia - Pipeline by AlzProtect SAS, H1 2017 Dementia - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Dementia - Pipeline by Anavex Life Sciences Corp, H1 2017 Dementia - Pipeline by Asceneuron SA, H1 2017 Dementia - Pipeline by Axon Neuroscience SE, H1 2017 Dementia - Pipeline by Axovant Sciences Ltd., H1 2017 Dementia - Pipeline by BioArtic AB, H1 2017 Dementia - Pipeline by Biogen Inc, H1 2017 Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Dementia - Pipeline by Cortice Biosciences Inc, H1 2017 Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2017 Dementia - Pipeline by Eisai Co Ltd, H1 2017 Dementia - Pipeline by Eli Lilly and Company, H1 2017 Dementia - Pipeline by H. Lundbeck A/S, H1 2017 Dementia - Pipeline by Heptares Therapeutics Ltd, H1 2017 Dementia - Pipeline by HSRx Group, H1 2017 Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 Dementia - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017 Dementia - Pipeline by Immungenetics AG, H1 2017 Dementia - Pipeline by ImStar Therapeutics Inc, H1 2017 Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017 Dementia - Pipeline by Intellect Neurosciences Inc, H1 2017 Dementia - Pipeline by INVENT Pharmaceuticals Inc, H1 2017 Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 Dementia - Pipeline by M3 Biotechnology Inc, H1 2017 Dementia - Pipeline by MediPost Co Ltd, H1 2017 Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017 Dementia - Pipeline by Neurimmune Holding AG, H1 2017 Dementia - Pipeline by Neuropore Therapies Inc, H1 2017 Dementia - Pipeline by NsGene A/S, H1 2017 Dementia - Pipeline by Oryzon Genomics SA, H1 2017 Dementia - Pipeline by P2D Bioscience, H1 2017 Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017 Dementia - Pipeline by Pharmasum Therapeutics AS, H1 2017 Dementia - Pipeline by Prana Biotechnology Ltd, H1 2017 Dementia - Pipeline by Sage Therapeutics Inc, H1 2017 Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017 Dementia - Pipeline by Stelic Institute & Co Inc, H1 2017 Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2017 Dementia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Dementia - Pipeline by Suven Life Sciences Ltd, H1 2017 Dementia - Pipeline by Sylentis SAU, H1 2017 Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2017 Dementia - Pipeline by Voyager Therapeutics Inc, H1 2017 Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017 Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017 Dementia - Dormant Projects, H1 2017 Dementia - Dormant Projects, H1 2017 (Contd..1), H1 2017 Dementia - Dormant Projects, H1 2017 (Contd..2), H1 2017 Dementia - Dormant Projects, H1 2017 (Contd..3), H1 2017 Dementia - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
